Yes, it is safe to start metformin with an eGFR of 74 mL/min/1.73 m²
Metformin can be safely initiated at this level of kidney function without dose adjustment, as an eGFR of 74 mL/min/1.73 m² is well above all safety thresholds established by the FDA and current diabetes guidelines. 1, 2
Clear Safety Thresholds
The FDA-approved prescribing information establishes explicit eGFR cutoffs for metformin use 2:
- Contraindicated: eGFR <30 mL/min/1.73 m²
- Do not initiate: eGFR 30-45 mL/min/1.73 m²
- Safe to initiate: eGFR ≥45 mL/min/1.73 m²
- Reassess benefit/risk if eGFR falls below 45 during ongoing therapy
Your patient's eGFR of 74 mL/min/1.73 m² places them in the safe zone, approximately 30 points above the threshold where initiation becomes restricted.
Dosing Recommendations
At this eGFR level, use standard metformin dosing 2:
- Starting dose: 500 mg twice daily OR 850 mg once daily with meals
- Titration: Increase by 500 mg weekly or 850 mg every 2 weeks based on glycemic control
- Maximum dose: 2,550 mg/day in divided doses (doses >2,000 mg better tolerated as three times daily)
- No dose reduction required until eGFR falls below 45 mL/min/1.73 m²
Monitoring Requirements
While safe to initiate, establish a monitoring plan 1, 2:
- Assess eGFR at least annually in all patients on metformin
- More frequent monitoring if patient is elderly or at risk for renal function decline
- Reassess benefit/risk if eGFR later falls below 45 mL/min/1.73 m²
- Discontinue if eGFR falls below 30 mL/min/1.73 m²
Evidence Supporting Safety
Large-scale real-world evidence confirms metformin safety at this eGFR range. A community-based cohort study of 75,413 patients found metformin was not associated with increased acidosis risk at eGFR 45-59 or 30-44 mL/min/1.73 m², with increased risk only emerging at eGFR <30 mL/min/1.73 m² (HR 2.07) 3. A systematic review similarly showed no increased acidosis risk except at eGFR <30 mL/min/1.73 m² 4.
Critical Situations Requiring Temporary Discontinuation
Even with normal kidney function, temporarily stop metformin in these scenarios 2:
- Iodinated contrast procedures if eGFR 30-60 mL/min/1.73 m² (restart after 48 hours if renal function stable)
- Acute illness with risk of volume depletion or hypoperfusion
- Surgery or procedures requiring restricted food/fluid intake
- Conditions causing hypoxemia: acute heart failure, sepsis, shock, acute MI
- Acute liver disease or excessive alcohol intake
These situations increase lactic acidosis risk regardless of baseline eGFR 2.
Additional Benefits at This eGFR Level
The 2025 ADA guidelines emphasize that metformin remains first-line therapy for type 2 diabetes with CKD 1. At eGFR 74 mL/min/1.73 m², the patient retains full glucose-lowering efficacy while potentially benefiting from cardiovascular risk reduction observed in observational studies 5.
Common Pitfall to Avoid
Do not unnecessarily withhold metformin based on outdated creatinine-based restrictions. The 2016 FDA guidance shift from serum creatinine to eGFR-based dosing expanded the pool of patients who can safely receive metformin 1. An eGFR of 74 mL/min/1.73 m² represents Stage 2 CKD (mild reduction) where metformin is unequivocally safe to initiate.